The Miller Laboratory is dedicated to understanding neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and dementias in order to develop new, effective, and safe treatments. We focus on translational neuroscience, new therapeutic approaches for neurodegenerative diseases, and precision medicine.

WHAT WE DO

ALS Research

The Miller Lab seeks to understand the pathogenesis of ALS with basic studies focused on SOD1, C9ORF72, TBK-1,  miRNA, protein misfolding, protein kinetics, and genetic modifiers of disease. We employ RNA-targeted therapeutic strategies, mainly using antisense oligonucleotides.

Learn More

Dementia Research

The Miller Lab studies how the various isoforms of the protein tau affect neurodegeneration. We employ RNA-targeted therapeutic strategies using antisense oligonucleotides to develop therapies for dementias involving the tau protein as well as for TREM-2.

Learn More

LATEST NEWS

Promising Results for Investigational Treatments for Inherited ALS

Physician's WeeklyJuly 9, 2020
Two preliminary studies were published simultaneously in the New England Journal of Medicine, both aimed at reducing superoxide dismutase 1 (SOD1) protein levels in people who had amyotrophic lateral sclerosis (ALS) due to SOD1 mutations. In the first study, a phase I/II trial of intrathecal tofersen, Timothy Miller, MD, PhD, of Washington University in St. […]

Experimental drug shows promising results for rare form of ALS

St. Louis Post-DispatchJuly 9, 2020
Researchers led by a Washington University neurologist found promising results for an experimental drug to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease.

HOW YOU CAN HELP

Join our email list

Receive updates from the Miller Lab. 

Sign Up Now

Donate

Help develop new treatments, therapies and cures.

Donate Now